Atlas Trials

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

Clinical trial NCT05408221 · UNKNOWN

Trial details

NCT number
NCT05408221
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2022-11-11
Primary completion
2025-08-01
Enrollment
576

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.